Investigating how the Hippo pathway affects scleroderma development
Role of the Hippo pathway in scleroderma pathogenesis
This study is looking at how a specific cell signaling pathway might be involved in scleroderma, a condition that thickens the skin and can impact other organs, to help find new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11013342 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the Hippo signaling pathway in the development of scleroderma, a disease that causes thickening of the skin and can affect internal organs. By utilizing advanced techniques like single-cell sequencing, the researchers aim to explore how specific cells interact and contribute to the fibrosis seen in scleroderma. The study will investigate the mechanisms behind these cellular changes and how they relate to the disease's progression, potentially leading to new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with scleroderma, particularly those experiencing significant skin and organ involvement.
Not a fit: Patients with scleroderma who are not actively experiencing symptoms or those with other unrelated autoimmune conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or even reverse the effects of scleroderma.
How similar studies have performed: Previous research has shown promising results in understanding the role of signaling pathways in autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Gudjonsson, Johann Eli — University of Michigan at Ann Arbor
- Study coordinator: Gudjonsson, Johann Eli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.